Background
Interspinous spacer (ISPs) was a promising treatment method for adjacent segment degeneration (ASD) after spinal fusion. Coflex, one of ISPs, has been deceived to prevent or decelerate ASD after spinal fusion, while the proof of the effectiveness of such device is still very limited. The purpose of this study was further to investigate the protection role of Coflex in vivo after spinal fusion, when implanted in adjacent segment and middle segment.
Methods
Three groups of beagles were allocated as follows (n=6): (1)L4-5 lumbar interbody fusion(IF). (2) L4-5 lumbar interbody fusion +L5-6 interspinous Coflex implantation(Cof1).(3) L4-5 and L6-7 interbody fusion+ L5-6 interspinous Coflex implantation (Cof2). In all animals, L5-6 discs were punctured to generate degeneration, and the intact L2–3 disc served as a noninjuries control (Con group). The effectiveness of Coflex on the prevention or deceleration of the progression of ASD was determined by magnetic resonance imaging, gross anatomical observation, histological and immunohistochemically analysis, and Real-time PCR analysis of gene expression.
Results
The objective disc in every group showed degeneration, however, the degeneration was more significant in IF group than Cof1 and Cof2 groups. MRI and histologic assay demonstrated that the discs of Cof1 and Cof2 groups maintained a relatively well-preserved structure as compared to the discs of IF group. Furthermore, immunohistochemistry analysis and real-time PCR demonstrated that the indicators of disc degeneration, TIMP1, BMP2, Col I, were up-regulated and disc matrix gene, Col II was down-regulated in IF group significantly
Conclusions
Coflex could decelerate the progression of ASD after spinal fusion, and it holds the same value not only at adjacent segment after single level spinal fusion, but also dose at the middle segment after “skipped” level (nonconsecutive) fusion